Switch View
© BusinessWire
12.11.2025
ISIN: US4364401012
Hologic Inc
HOLX
LISTED
NASDAQ
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
News Preview
Hologic, Inc. (Nasdaq: HOLX) announced today that its Genius™ Digital Diagnostics System achieved expanded CE marking in the European Union and is now approved to image and review both cell and tissue specimens. Previously, the system was CE marked specifically for cell analysis, notably used in cervical cancer screening, among other applications....
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often di...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ISIN: US54948X1090
Lucid Diagnostics Inc.
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement milestones
Multi-Jurisdictional Contractor Advisory Committ...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
12.11.2025
ISIN: US6700021040
Novavax Inc
NVAX
LISTED
NASDAQ
Novavax to Participate in Jefferies London Healthcare Conference
News Preview
GAITHERSBURG, Md., Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
12.11.2025
ISIN: CA46604F1099
Izotropic Corporation
IZO
LISTED
CSE
Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation
News Preview
Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - November 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Natera Integrates with Flatiron Health’s OncoEMR® Platform
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera’s oncology testing portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Reco...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US81728J1097
Sensus Healthcare, Inc.
SRTS
LISTED
NASDAQ
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors
News Preview
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company’s Board of Directors. Mr. Sachetta is filling the vacancy that resulte...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US00846U1016
Agilent Technologies Inc
A
LISTED
NYSE
Agilent Research Catalyst (ARC) Award Presented to UC Davis for Breakthroughs in Peptide Therapeutics
News Preview
Agilent Technologies Inc. (NYSE: A) today announced that the University of California has received an Agilent Research Catalyst (ARC) award on behalf of Professor Marie Heffern at the UC Davis campus. The award recognizes Professor Heffern’s innovative research into the analytical characterization of peptide and protein therapeutics targeting incr...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US22407B1089
Coya Therapeutics, Inc.
COYA
LISTED
NASDAQ
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025.
Recent Corporat...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US8835561023
Thermo Fisher Scientific Inc
TMO
LISTED
NYSE
Thermo Fisher Scientific Receives 510(k) Clearance in the United States for EXENT System* to Aid in the Diagnosis of Multiple Myeloma
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories. The EXENT System combines enhanced sensitivity and automation to provide accurate results, helping clini...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
“We believe that the proposed transaction with BioCryst provides the best oppor...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
“Thes...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
12.11.2025
ISIN: US03836J1025
Aprea Therapeutics Inc
APRE
LISTED
NASDAQ
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
News Preview
DOYLESTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the third quarter ende...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX SHAREHOLDER ALERT: BFA Law Notifies MoonLake Immunotherapeutics Investors of Important December 15 Securities Class Action Deadline for Investors seeking Recovery
News Preview
New York, New York--(Newsfile Corp. - November 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
INSP SHAREHOLDER ALERT: BFA Law Notifies Inspire Medical Systems, Inc. Investors of Important January 5 Securities Class Action Deadline for Investors seeking Recovery
News Preview
New York, New York--(Newsfile Corp. - November 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US7133171055
PepGen Inc
PEPG
LISTED
NASDAQ
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new composition of matter pa...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: CA92767B1058
Vireo Growth Inc
VREO
LISTED
CSE
Vireo Growth Inc. Announces Third Quarter 2025 Results
News Preview
Q3 GAAP revenue of $91.7 million increased 264% year-over-year, driven by recently closed M&A transactions and organic growth throughout the portfolio...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US14817C1071
Cassava Sciences Inc
SAVA
LISTED
NASDAQ
Cassava Reports Q3 2025 Financials Results and Provides Business Update
News Preview
AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third qu...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US69353Y1038
PMV Pharmaceuticals Inc
PMVP
LISTED
NASDAQ
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
News Preview
PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate updat...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US21833P3010
Corbus Pharmaceuticals Holdings Inc
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US19459J1043
Collegium Pharmaceutical Inc
COLL
LISTED
NASDAQ
Collegium to Participate in Upcoming Investor Conferences
News Preview
STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US28659T2006
Elite Pharmaceuticals, Inc.
ELTP
LISTED
OTC
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
News Preview
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) fo...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US7133171055
PepGen Inc
PEPG
LISTED
NASDAQ
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025.
“This quarter was d...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer,...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US3179701012
Firefly Neuroscience, Inc.
AIFF
LISTED
NASDAQ
Firefly Neuroscience Reports Third Quarter 2025 Financial Results
News Preview
– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line –...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON plc to Present at the Jefferies London Healthcare Conference
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT.
Any changes to this event and links to the live webcast (where available)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US21900C3088
CorMedix Inc
CRMD
LISTED
NASDAQ
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
News Preview
‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US98419J2069
XOMA Royalty Corp
XOMA
LISTED
NASDAQ
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
News Preview
Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics....
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: CA22587M1068
Cresco Labs Inc
CL
LISTED
CSE
Cresco Labs Launches Flagship Flower Brand in Germany
News Preview
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the launch of Cresco-branded flower in Germany, marking the Company’s first commercial entry into the European Union. The launch reflects Cresco’s expanded growth strategy as it pilots new investment platforms beyond U.S. cannabis.
Germany is o...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US45175G2075
ImageneBio, Inc
IMA
LISTED
NASDAQ
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
News Preview
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US98937L1052
Zenas BioPharma, Inc.
ZBIO
LISTED
NASDAQ
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US00509G2093
Acumen Pharmaceuticals Inc
ABOS
LISTED
NASDAQ
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third qua...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US44486Q1031
Humacyte Inc
HUMA
LISTED
NASDAQ
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - ...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US36269B1052
Gain Therapeutics, Inc.
GANX
LISTED
NASDAQ
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
News Preview
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US89854M1018
TScan Therapeutics, Inc.
TCRX
LISTED
NASDAQ
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US52490G1022
Legend Biotech Corp
LEGN
LISTED
NASDAQ
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
News Preview
SOMERSET, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2025 unaudited financial results and key corporate highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US07373V1052
Beam Therapeutics Inc
BEAM
LISTED
NASDAQ
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
News Preview
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025, at 3:30 p.m. GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US04317A1079
Artiva Biotherapeutics, Inc.
ARTV
LISTED
NASDAQ
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Artiva Q3 2025 Financial Release and Business Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US6904691010
Ovid Therapeutics Inc
OVID
LISTED
NASDAQ
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
News Preview
Earnings release and leadership...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US7743743004
Rockwell Medical Inc
RMTI
LISTED
NASDAQ
Rockwell Medical Announces Third Quarter 2025 Results
News Preview
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2025.
"During the third quarter, we cont...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.11.2025
ISIN: US87975F1049
Telomir Pharmaceuticals, Inc.
TELO
LISTED
NASDAQ
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
News Preview
New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action. MIAMI, FL / ACCESS Newswire / November 12, 2025 / Telomir Pharmaceuticals, Inc. (NASD...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.11.2025
ISIN: CH1243598427
Sandoz Group AG
SDZ
LISTED
XWSX
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
News Preview
Sandoz Group AG
/ Key word(s): Agreement
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab 12.11.2025 / 07:35 CET/CEST
Agreement with EirGenix Inc. grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment of HER2-positive early breast cancer / met......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im Bereich Protein Degradation
News Preview
Meilenstein-Zahlung spiegelt kontinuierliche Fortschritte im Rahmen der strategischen Forschungskooperation wider, die sich auf Patientengruppen mit komplexen oder hohen Versorgungsbedürfnissen fokussiert
Genehmigung des IND-Antrags durch die FDA löst Meilenstein-Zahlung in Höhe von 5 Mio. US$ an Evotec aus
Hamburg, 12. November 2025:......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership
News Preview
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations
FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec
Hamburg, Germany, 12 November 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WK......
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: FR0012616852
Abionyx Pharma S.A.
CEREN
LISTED
EURONEXT
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
News Preview
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced strategic discussions with IHU SEPSIS, the world’s first and largest integrated center fully dedicated to the research, training, and clinical management of se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.11.2025
ISIN: US03209R1032
Amphastar Pharmaceuticals Inc
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: CH0256379097
Molecular Partners AG
MOLN
LISTED
SIX
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
News Preview
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (NASDAQ: PRLD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
News Preview
Châtillon, France, November 11, 2025...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
News Preview
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: US0144421072
Alector Inc
ALEC
LISTED
NASDAQ
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
News Preview
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH DEADLINE ALERT: ROSEN, A TOP RANKED GLOBAL LAW FIRM, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
News Preview
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If you pu...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK
News Preview
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
News Preview
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.SO WHAT...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
TVRD SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
News Preview
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, W...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP
News Preview
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQURE N.V. (“uniQURE” or the “Company”) (NASDAQ:QURE) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
Wh...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
UPCOMING DEADLINE: Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
